Peter McSweeney
Hematology & Oncology · Denver, CONPI 1881678449
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $97,230 of the $125,583 with a category attached, or 77.4%. Gilead accounts for 97.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $65,754 and has fallen 99.9% since, to $84 in 2025. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $770.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$122K
- TG Therapeutics, Inc.$2K
- Novartis$625
- AbbVie$142
- Rigel Pharmaceuticals, Inc.$63
- Sanofi$57
- plus $321 from 12 others
Across 156 payments — averaging $4903.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$479K
- Novartis$285K
- Autolus Inc$925
What the payments were for
- Consulting fees$10,5258%
- Speaking & faculty fees$97,23077%
- Travel & lodging$13,44911%
- Food & beverage$4,3593%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 120 | $122,388 |
| TG Therapeutics, Inc. | 5 | $1,987 |
| Novartis | 9 | $625 |
| AbbVie | 7 | $142 |
| Rigel Pharmaceuticals, Inc. | 1 | $63 |
| Sanofi | 2 | $57 |
| Bristol Myers Squibb | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Incyte Corporation | 2 | $30 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $29 |
| Pfizer | 2 | $27 |
| Mesoblast, Inc. | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Merck | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$125,583 in reported general payments places this provider in the 90th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Denver
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- Robert RifkinDenver$270K
- Mabel MardonesDenver$149K
- Peter ForsbergDenver$147K
- Alireza EghtedarDenver$96K
- Jeffrey MatousDenver$93K
- Tara GregoryDenver$67K
- Michael TeesDenver$56K
- Marcello RottaDenver$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.